Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas

Miki Ohira,1,8 Shigeyuki Oba,2,8 Yohko Nakamura,1 Eriko Isogai,1 Setsuko Kaneko,3 Atsuko Nakagawa,4 Takahiro Hirata,5 Hiroyuki Kubo,5 Takeshi Goto,5 Saichi Yamada,6 Yasuko Yoshida,6 Misa Fuchioka,7 Shin Ishii,2 and Akira Nakagawara1,*

1Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
2Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan
3Department of Pediatric Surgery, University of Tsukuba School of Medicine, Tsukuba 305-8575, Japan
4Second Department of Pathology, Aichi Medical University, Nagakute 480-1195, Japan
5Hisamitsu Pharmaceutical Co. Inc., Tokyo 100-622, Japan
6Micro Ceramics Laboratory, R & D Center, NGK Insulators, LTD, Nagoya 467-8530, Japan
7Center for Molecular Biology and Cytogenetics SRL Inc., Tokyo 191-0002, Japan
8These authors contributed equally to this work.
*Correspondence: akiranak@chiba-cc.jp

Summary

To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10^{-4}), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.

Introduction

Neuroblastoma is one of the most common solid tumors in children and originates from the sympathoadrenal lineage of the neural crest (Bolande, 1974). Its clinical behaviors are heterogeneous. The tumor, when developed in infants, frequently regresses spontaneously by inducing differentiation and/or programmed cell death. When developed in children over 1 year of age, however, the tumor is often aggressive and acquires resistance to intensive chemotherapy. Although recent progress in therapeutic strategies against advanced neuroblastoma has improved patient survival, long-term outcomes still remain very poor. Furthermore, part of neuroblastomas categorized to the intermediate group (stage 3 or 4 tumors that possess a single copy of the MYCN gene) often recurs after complete response to initial therapy. Such differences in the final outcomes of the tumor are considered presumably attributable to differences in genetic and biological abnormalities, which are reflected in the gene and protein expression profiles of the tumor.

The prediction of cancer prognosis is one of the most urgent demands to initiate the treatment of neuroblastoma. As expected from the natural course of neuroblastoma, patient age at diagnosis (over or under 1 year of age) is an important prognostic factor (Evans et al., 1971). Disease stage is also a powerful indicator for neuroblastoma prognosis (Brodeur et al., 1993). Moreover, recent advances in basic research have discovered several molecular markers that are useful in clinical practice, including amplification of the MYCN oncogene (Schwab et al., 1983; Brodeur et al., 1984), DNA ploidy (Look et al., 1984; Look et al., 1991), deletion of chromosome 1p (Brodeur et al., 1988), and TrkA expression (Nakagawara et al., 1992; Nakagawara et al., 1993). Other indicators also include telomerase (Hiyama et al., 1995), CD44 (Favrot et al., 1993), pleiotrophin (Nakagawara et al., 1995), N-cadherin (Shimono et al., 2000), CDC10 (Nagata et al., 2000), and Fyn (Berwanger et al., 2002). However, the combinations thereof still frequently fail to predict patient outcome. In the post-genome sequence era, therefore, the advent of new diagnostic tools has been ex-
pected. Recently, the DNA microarray method, applied to comprehensively demonstrate expression profiles of primary neuroblastomas and cell lines, has already identified the following: (1) differences in gene expression between favorable and unfavorable subsets (Yamanaka et al., 2002; Berwanger et al., 2002); and (2) differences in gene expression that occur during retinoic acid-induced neuronal differentiation (Ueda, 2001). However, a study to predict neuroblastoma prognosis with a microarray using a large number of neuroblastoma samples has never been reported. We have recently isolated 5500 genes from the cDNA libraries, which were generated from primary neuroblastomas, part of which has previously been reported (Ohira et al., 2003a; Ohira et al., 2003b). In this study, to identify genes strongly associated with neuroblastoma prognosis and to apply them to make a really practical cDNA microarray for neuroblastoma diagnosis, we constructed an in-house, ink-jet-printed cDNA microarray carrying 5340 genes proper to neuroblastoma and applied it to analyze 136 samples. After selecting genes significantly related to patient prognosis, we made a mini-chip carrying 200 top-ranked genes to apply for the clinic.

There have been many attempts to predict cancer outcome using microarray. A reliable prediction for outcomes of cancer patients naturally demands its reproducibility, and it is quite important to use sound and highly reliable statistical methodologies; a complete crossvalidation analysis without introducing any information leakage and an independent test using new samples are necessary. As Ntzani and Ioannidis (2003) pointed out, however, such a careful methodology has often been ignored in most microarray studies. We here developed a supervised classification method without any information leakage as a statistic tool and demonstrated that the probabilistic output of the analysis defines the molecular signature of neuroblastoma to predict its prognosis. Although the construction of the statistical tool was based on one of the most reliable statistical tests, we also consulted a validation test for an independent experiment examining 50 samples (whose RNAs were prepared in an independent laboratory) by using the mini-chip. The high performance for the outcome prediction by the mini-chip system suggests the high feasibility of developing a clinical tool based on molecular signature.

Results

Neuroblastoma proper cDNA microarray
The whole scheme of our study is summarized in Figure 1. We first constructed a neuroblastoma proper cDNA microarray harboring the spots of 5340 genes on a slide glass by using a ceramics-based ink-jet printing system (the 5340 genes system). This in-house cDNA microarray appeared to have overcome the previous problems caused by pin-spotting, e.g., uneven quantity or shape of individual spots on an array. Ten micrograms of each of the total RNA extracted from 136 frozen tissues of primary neuroblastomas were labeled with Cy3 dye. As a common reference, the mixture of the total RNA obtained from four neuroblastoma cell lines with a single copy of MYCN (NB69, NBLS, SK-N-AS, and SH-SY5Y) was labeled with Cy5 dye.

We first evaluated the quality of our cDNA microarray, the 5340 genes system. The log Cy3/Cy5 fluorescence ratio of each gene spot was normalized to eliminate intensity-dependent biases. Since the 5340 genes array contains 260 duplicated or multiplicated genes, the expression ratio of such a duplicated gene was represented by the average of multiple spots. Based on estimation performance for missing values (see the Supplemental Data available with this article online) and on reproduction variance of the duplicated genes, the standard deviation for the log ratio of a single gene was sufficiently small, ranging between about 0.2 and about 0.3 (Figure S1A). The scatter plots of the log Cy3/Cy5 fluorescence ratio between duplicated gene spots in the 136 experiments and those between repeated experiments also indicated high reproducibility of spotting and experiment (Figures S1B and S1C). These suggest that the production of and experiments by our cDNA microarray are highly reproducible.

Supervised classification
To develop a statistical tool that predicts the prognosis of a new patient with neuroblastoma, we introduced a supervised classification. In the development, we used 136 neuroblastomas, randomly selected tumor samples from the neuroblastoma tissue bank, consisting of 41 stage 1 tumors, 22 stage 2 tumors, 33 stage 3 tumors, 28 stage 4 tumors, and 12 stage 4S tumors. The follow-up duration ranged between 3 and 241 months (median, 56 months, mean, 57.3 months) after diagnosis. The left panel in Figure 2 compiles summary information of each sample, including survival time and important prognosis markers (see Experimental Procedures for details). Since variations in follow-up duration generated noises in the supervised classification, we used patient outcome (dead or alive) at 5 years after diagnosis as the target label to be predicted. Since the outcomes of 40 of 136 samples were unknown at 5 years after diagnosis, data for 96 remaining samples were used subsequently. When we were interested in short-term outcome prediction, the target label was set at 2 years after diagnosis, for which purpose 126 samples out of the 136 samples were used.

We constructed the weighted voting as a supervised classifier after important genes were selected according to pairwise F scores. To estimate the prediction accuracy for new data, we consulted leave two out (LTO) analysis, which obtains almost unbiased estimation of prediction accuracy for new data while avoiding overestimation due to information leakage (Figure S2A). Although it is known that the prediction accuracy of a supervised classifier depends on the number of genes to be used (Figure S3), the LTO procedure enables us to optimize it without introducing information leakage, by using a sample left out at the outer loop of the double-loop procedure (see Experimental Procedures). The crossvalidation accuracy for the 5 year prognosis prediction was as high as 88.5% (sensitivity of 86.7% and specificity of 89.4%) (Table 1, “Whole cases”). In the LTO analysis, we selected genes and constructed the corresponding classifier individually for the outcome prediction of each sample. The average number of the selected genes, n, was 30.7. If we applied the same procedure to the short-term (2 year) prediction, the accuracy, sensitivity, and specificity were 89.8%, 88.0%, and 90.2%, respectively (data not shown).

Construction of a probabilistic output
According to the LTO analysis, we can obtain weighted vote values and the corresponding survival rates. After approximat-
ing nonlinear transformation from weighted vote values to the survival rates, the transformation outputs the reliability of each sample’s outcome prediction as a probabilistic output, posterior probability. We suppose each posterior probability, a real number between 0 and 1, corresponds to the expected 5 year survival rate. The right upper panel of Figure 2 shows the predictions for the 136 samples as posterior probabilities. Most of the samples alive at 5 years after diagnosis (blue mark) are found to have posterior values near 1, while most of the dead samples (red mark) have those near 0. It is known that it is difficult to predict the prognosis of neuroblastoma patients of the intermediate risk group (the type II subset: stage 3 or 4, without amplification of MYCN), denoted by green area. The posterior values are likely to take intermediate values near 0.5; however, their binarization after being separated by threshold 0.5 shows good accordance with the actual outcome. Frequencies of posterior values for alive and dead samples are shown in the right middle panel. The rate of alive samples among the whole samples, which denotes the actual survival rate, is plotted against each posterior value in the right bottom panel in Figure 2; this panel shows the good correspondence between the posterior value and the survival rate.

Probabilistic outputs are considered to be advantageously useful as compared with conventional binary outputs when used in making a clinical assessment and may be considered identical to them if establishing an appropriate threshold value. The real-valued posterior can be used for categorization into arbitrary number of groups. For example, dividing the posterior values into three by setting thresholds 0.3 and 0.7, we obtain three groups whose survival curves are significantly different from each other; this tertiary categorization provides another definition of intermediate risk group based only on expression patterns (Figure S4).

Comparing the survival curves

Figure 3A shows survival curves for favorable and unfavorable patients predicted by the classifier with a binary threshold (0.5). The 5 year survival rate for the former (n = 98) was as good as 94%, while that for the latter (n = 38) was as poor as 33% (p < 10^{-5}). When 70 sporadic neuroblastomas were evaluated after excluding the tumors found by mass screening, the 5 year survival rate for the former (n = 40) was 85%, while that for the latter (n = 30) was 20% (p < 10^{-5}) (Figure 3B). To further evaluate the efficiency of our system, we calculated the posterior value for the intermediate subset of neuroblastoma (type II), whose prognosis is usually difficult to predict. As shown in Figure 3C, the survival curves were significantly categorized into two groups. The 5 year survival rate of patients who were predicted as favorable was 89%, while that for unfavorable patients was 36% (p = 0.000067). Since the age at diagnosis (≥1 year) is currently used as a poor prognostic factor for the type II tumors, we examined the ability of the classifier for the older patients with type II tumors. Even for such patients whose prognosis is difficult to predict, the survival rate (45%) of all 18 patients was divided solely by gene expression into the group with favorable prognosis (n = 10; 73%) and that with poor outcome (n = 8; 13%) (Figure 3D). In addition, if the intermediate risk group was further separated into stage 3 tumor group and stage 4 tumor group, the posterior value was significantly related to the survival, especially for stage 3 tumors (Figure S5). These results suggest that the posterior value obtained by our statistical analysis highly efficaciously allows the classification of patient outcomes, even when the tumor is of the intermediate type.

We further compared our results to existing prognosis markers in Table 1 and found that the supervised microarray analysis showed the best sensitivity-specificity balance among the prognostic factors for predicting the outcome of neuroblastoma. When the classifier is combined with the age at diagnosis, the disease stage (stage 1, 2, or 4s versus stage 3 or 4) and the MYCN amplification, accuracy, sensitivity, and specificity increased up to 95.8%, 93.3%, and 97.0%, respectively. Although the currently used markers (age, stage, and MYCN)
**Figure 2.** Posterior probability of survival at 5 years

Posterior probability of survival at 5 years for 136 training data samples, output by the leave two out (LTO) crossvalidation without any information leakage. Left panel: Neuroblastoma samples. A red or blue horizontal line denotes survival period after diagnosis for a dead or alive patient, respectively. Red and blue marks denote various clinical properties of patients; see text below the panel for detailed explanation. Background colors show groups determined by stage and MYCN amplification status: red, type III, with MYCN amplification; green, type II, with single copy of MYCN at unfavorable stage (3 or 4); and blue, type I, with single copy of MYCN and at favorable stage (1, 2, or 4). Right upper panel: The LTO crossvalidated prediction (posterior) for each patient; a red or a blue mark denotes that the patient is dead or alive at 5 years, respectively. Right middle panel: Cumulative smooth histogram of posterior probabilities for patients of dead (red), alive (blue), and unknown (white) at 5 years after diagnosis. Right lower panel: The horizontal and vertical axes denote the posterior and the empirical probability of 5 year survival, i.e., the ratio of the smooth histogram values between dead and alive patients, shown in the middle panel, respectively. Because the border between dead and alive samples is close to the white broken line \(x = y\), the posterior can be regarded as a 5 year survival chance rate.
Table 1. Accuracy of each marker for prognosis prediction (5 years after diagnosis)

<table>
<thead>
<tr>
<th>Marker</th>
<th>Whole cases</th>
<th>Sporadic cases</th>
<th>Intermediate and old age*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n cases</td>
<td>accuracy</td>
<td>sensitivity</td>
<td>specificity</td>
</tr>
<tr>
<td>Microarray classifier</td>
<td>136</td>
<td>89%</td>
<td>87%</td>
</tr>
<tr>
<td>Age (less than 1 year old)</td>
<td>136</td>
<td>81%</td>
<td>83%</td>
</tr>
<tr>
<td>Stages (1, 2, and 4s)</td>
<td>136</td>
<td>83%</td>
<td>97%</td>
</tr>
<tr>
<td>Shimada classification (unfavorable)</td>
<td>62</td>
<td>87%</td>
<td>78%</td>
</tr>
<tr>
<td>Hyperdiploidy (aneuploidy)</td>
<td>62</td>
<td>72%</td>
<td>67%</td>
</tr>
<tr>
<td>MYCN amplification</td>
<td>136</td>
<td>89%</td>
<td>67%</td>
</tr>
<tr>
<td>Microarray + age + stages + MYCN*</td>
<td>136</td>
<td>96%</td>
<td>93%</td>
</tr>
</tbody>
</table>

Sensitivity specificity is the rate of unfavorably/favorably predicted samples, i.e., LTO posterior <0.5>/>0.5, among actually unfavorable/favorable samples. Microarray classifier, supervised classification based on the microarray data. *By this classifier, all patients with the MYCN amplification are predicted as unfavorable, and all patients with a single copy of MYCN and at stage 1, 2, or 4s are predicted as favorable. In the remaining intermediate samples (with a single copy of MYCN and at stage 3 or 4), the patients with age <1 year are predicted as favorable, and the microarray predictions are applied for those with age >1 year.

Also showed good potential to predict generally but less than the microarray, these exhibited only 64% accuracy of prediction for the type II tumors with ≥1 year of age (Table 1). Together with the results of survival analysis, the microarray classifier is revealed to be a powerful predictor to classify such group of neuroblastomas (86% accuracy; Table 1).

Practical application of 200 cDNAs microarray and independent test

For the practical use in the clinic, a cDNA microarray system that contains cDNA spots of a relatively small number and hence is easy to treat is expected. According to our gene selection based on the pairwise F score, the numbers of genes that were appropriate for the 5 year and 2 year prognosis prediction for all available samples were 10 and 70, respectively. In order for the system to reserve the applicability to short-term and long-term outcome prediction simultaneously, we selected 200 top-ranked genes according to the pairwise F scores in the 2 year prediction, because the 2 year prediction required larger variety of genes, and then made a smaller cDNA microarray system carrying the 200 genes. The newly designed microarray system (the mini-chip system) was evaluated by being hybridized with 5 μg total RNA obtained from 50 independent test samples. To preserve the independence of experimental procedure, these RNAs were prepared and hybridized in a different laboratory from the original experiments of 136 samples with the 5340 genes system (see Experimental Procedures). Although the weight values in the weighted voting classifier were determined by the 5340 genes system without any information leakage from the 50 independent samples, the result was as good as that obtained by the 5340 cDNA microarray analysis (90% [45/50] for 2 year, and 87.8% [43/50] for 5 year prognosis prediction; Figure 4B). This test validated not only the prediction robustness of our classifier constructed by the 5340 genes system, but also the construction procedure of the mini-chip system according to our gene selection based on pairwise F scores. When we reconstructed another supervised classifier by applying the LTO analysis to the 50 samples measured by the mini-chip system, the accuracy of the 5 year prediction was 91.8% (45/49) (Figure 4C). These results suggest...
three things. (1) The supervised classifier obtained by the statistical analysis by the 5340 genes system is reproducible even if it is applied to the data measured by the reduced 200 genes system. Note that the 50 samples were completely new data for the classifier in this case. (2) Our procedure to construct a supervised classifier according to the LTO analysis is also reproducible, because the same procedure was successful in making another classifier with a high prediction accuracy when applied to the data taken by the mini-chip system. (3) A simple, low-cost microarray system, the mini-chip system, is highly feasible for predicting the prognosis of neuroblastoma.

Genes selected for prognosis prediction
To assess the relationship between the clinically defined sub-sets of neuroblastoma and the expression of 70 genes that were selected as top scored with 2 year prognosis according to the pairwise F score, we conducted an unsupervised clustering analysis (Figure 5). As expected, part of the type II (intermediate) tumors of patients with a poor prognosis showed an expression pattern that was similar to that of the type III (unfavorable) tumors, and many of them died. On the other hand, expression profiles of the remaining type II tumors seemed to be heterogeneous similarly to those of the type I (favorable) tumors with a good outcome. Most of the tumors with highly expressed TrkA and hyperdiploidy, as well as tumors detected by mass screening, were included in the latter group. Table 2 shows a list of 41 genes that corresponded to the 70 top-scored genes and their p and q values (Storey and Tibshirani, 2003) in the log rank test, since we found that several genes were duplicated in the selected 70 genes. Based on the above clustering, these genes were categorized into two groups (group F and group UF; the gene groups strongly correlated with favorable and unfavorable prognosis, respectively) (Figure 5 and Table 2).

The genes in group F tended to show high levels of expression in the type I tumors, while those in group UF were highly expressed in the type III tumors. The former contained genes that were related to neuronal differentiation (tubulin α, peripheral, neuromodulin [GAP43], and HMP19) and genes that were related to catecholamine metabolism (dopamine β-hydroxylase [DBH], and tyrosine hydroxylase [TH]). On the other hand, the latter involved many members of genes that are related to protein synthesis (ribosomal protein genes such as RPL18A, RPLP0, RPL5, RPL4, and RPL7A as well as translation initiation and elongation factor genes EEF1G and EIF3SS) and genes that are related to me-
Figure 5. Expression profiles of 70 genes selected for predicting neuroblastoma prognosis at 2 years. Note that 10 genes for predicting prognosis at 5 years are also included in the 70 genes. The left and lower trees depict hierarchical clustering of the 136 neuroblastoma samples and the 70 genes selected in the present study, respectively. In the left tree, blue, green, and red colors denote “MYCN single and stage 1, 2 or 4s tumor” (type I, favorable), “MYCN single and stage 3, 4 tumor” (type II, intermediate), and “MYCN amplified tumor” (type III, unfavorable), respectively. The blue and red colors in the expression matrix show the high and low expression, respectively. A gene showing high expression level likely for unfavorable samples belongs to the group “UF” (red subtree in the lower tree), while one showing high expression likely for favorable samples belongs to the group “F” (blue subtree in the lower tree).

Note that 10 genes for predicting prognosis at 5 years are also included in the 70 genes. The left and lower trees depict hierarchical clustering of the 136 neuroblastoma samples and the 70 genes selected in the present study, respectively. In the left tree, blue, green, and red colors denote “MYCN single and stage 1, 2 or 4s tumor” (type I, favorable), “MYCN single and stage 3, 4 tumor” (type II, intermediate), and “MYCN amplified tumor” (type III, unfavorable), respectively. The blue and red colors in the expression matrix show the high and low expression, respectively. A gene showing high expression level likely for unfavorable samples belongs to the group “UF” (red subtree in the lower tree), while one showing high expression likely for favorable samples belongs to the group “F” (blue subtree in the lower tree).

tabolism (enolase 1 [ENO1] and transketolase [TKT]). The top 10 genes selected for the 5 year outcome prediction were RPL18A, ENO1, EEF1G, TUBA3, GNB2L1, ARHGEF7, GCC2, DDX1 (duplicated), and PRPH. The MYCN gene was also a member of 70 genes (group UF) as expected; however, it was outside of the top 10 genes for the 5 year label. Instead, DDX1, which is frequently coamplified with MYCN on chromosome 2p24, was a member of the top 10 genes (UF group) for both of the 2 year and 5 year labels. Confirmation of the differential expression of the selected genes was further conducted by
using representative 16 favorable and 16 unfavorable tumor samples that were independent of the 136 samples used in the present analysis, by semiquantitative RT-PCR (Figure S6; refer also to Ohira et al., 2003a). We also conducted immunohistochemical analysis for peripherin antibody using tissue sections prepared from primary neuroblastoma with favorable and unfavorable histology, since peripherin gene is a member of the top 10 genes for both 2 year and 5 year outcome prediction (Table 2). Peripherin protein was positively detected in the cytoplasm of neuroblastic cells as well as neuritis in all three favorable histology tumors (Figure S7, FH&NA). Two unfavorable histology tumors with poorly differentiated subtype, regardless of MYCN status, showed sporadic staining (less than 20% of the favorable histology tumor) for peripherin protein in neurites. Peripherin was completely negative in the unfavorable histology tumor of undifferentiated subtype (Figure S7, UF&NA). These results indicate the reliability of our gene selection. In the log rank test, p values of 18 of 20 genes in group F and of all 21 genes in group UF were less than 0.05 (Table 2), indicating that these 39 genes can be independent prognostic factors for primary neuroblastomas.

**Discussion**

Our study has disclosed the molecular signature of neuroblastoma that predicts patient outcomes by using RNA ob-

<table>
<thead>
<tr>
<th>Spot name</th>
<th>Accession number</th>
<th>Gene code</th>
<th>Chromosome map</th>
<th>Pattern</th>
<th>Log rank p</th>
<th>q value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nbla11606</td>
<td>NM_006009</td>
<td>TUBA3</td>
<td>12q13.12</td>
<td>F &gt; UF</td>
<td>0</td>
<td>0.000674</td>
</tr>
<tr>
<td>Nbla00890</td>
<td>NM_003989</td>
<td>ARHGEF7</td>
<td>13q34</td>
<td>F &gt; UF</td>
<td>0.000001</td>
<td>0.000743</td>
</tr>
<tr>
<td>Nbla00890</td>
<td>NM_006802</td>
<td>K-ALPHA4-1</td>
<td>12p13.12</td>
<td>F &gt; UF</td>
<td>0.000003</td>
<td>0.000926</td>
</tr>
<tr>
<td>Nbla12191</td>
<td>U7309</td>
<td>VPS41</td>
<td>7p14.1</td>
<td>F &gt; UF</td>
<td>0.000006</td>
<td>0.001096</td>
</tr>
<tr>
<td>Nbla30783</td>
<td>NM_006054</td>
<td>RTN3</td>
<td>11q13.1</td>
<td>F &gt; UF</td>
<td>0.00001</td>
<td>0.001282</td>
</tr>
<tr>
<td>Nbla11788</td>
<td>NM_006262</td>
<td>PRPH</td>
<td>12q13.12</td>
<td>F &gt; UF</td>
<td>0.000017</td>
<td>0.001522</td>
</tr>
<tr>
<td>Nbla10093</td>
<td>NM_001983</td>
<td>HADHB</td>
<td>2p23.3</td>
<td>F &gt; UF</td>
<td>0.000018</td>
<td>0.001541</td>
</tr>
<tr>
<td>Nbla22572</td>
<td>NM_000790</td>
<td>DDC</td>
<td>7p12.2</td>
<td>F &gt; UF</td>
<td>0.000035</td>
<td>0.00213</td>
</tr>
<tr>
<td>Nbla12170</td>
<td>NM_001915</td>
<td>CVB561</td>
<td>17q23.2</td>
<td>F &gt; UF</td>
<td>0.00016</td>
<td>0.002566</td>
</tr>
<tr>
<td>gene071</td>
<td>NM_003980</td>
<td>TH</td>
<td>11p15.5</td>
<td>F &gt; UF</td>
<td>0.000787</td>
<td>0.012173</td>
</tr>
<tr>
<td>Nbla03499</td>
<td>NM_002074</td>
<td>GNB1</td>
<td>1p36.33</td>
<td>F &gt; UF</td>
<td>0.000795</td>
<td>0.012237</td>
</tr>
<tr>
<td>Nbla04181</td>
<td>AK55112</td>
<td>AK55112</td>
<td>5q13.2</td>
<td>F &gt; UF</td>
<td>0.001425</td>
<td>0.017462</td>
</tr>
<tr>
<td>Nbla00487</td>
<td>AB075512</td>
<td>C8orf134</td>
<td>6p21.33</td>
<td>F &gt; UF</td>
<td>0.002751</td>
<td>0.025273</td>
</tr>
<tr>
<td>Nbla00269</td>
<td>NM_000787</td>
<td>DBH</td>
<td>9q34.2</td>
<td>F &gt; UF</td>
<td>0.00362</td>
<td>0.030407</td>
</tr>
<tr>
<td>Nbla22531</td>
<td>NM_002045</td>
<td>GAP43</td>
<td>3p13.31</td>
<td>F &gt; UF</td>
<td>0.004394</td>
<td>0.03475</td>
</tr>
<tr>
<td>Nbla22156</td>
<td>NM_014944</td>
<td>CLSTN1</td>
<td>1p36.22</td>
<td>F &gt; UF</td>
<td>0.005233</td>
<td>0.038274</td>
</tr>
<tr>
<td>Nbla00578</td>
<td>NM_006818</td>
<td>AF1Q</td>
<td>1q21.3</td>
<td>F &gt; UF</td>
<td>0.009397</td>
<td>0.05354</td>
</tr>
<tr>
<td>Nbla00217</td>
<td>NM_032638</td>
<td>GATA2</td>
<td>3q21.3</td>
<td>F &gt; UF</td>
<td>0.010245</td>
<td>0.056301</td>
</tr>
<tr>
<td>Nbla21394</td>
<td>NM_000743</td>
<td>CHRNA3</td>
<td>15q25.1</td>
<td>F &gt; UF</td>
<td>0.072464</td>
<td>0.162629</td>
</tr>
<tr>
<td>Nbla11993</td>
<td>NM_015980</td>
<td>HMP19</td>
<td>5q35.2</td>
<td>F &gt; UF</td>
<td>0.204274</td>
<td>0.282486</td>
</tr>
</tbody>
</table>

Although 70 clones were selected as important genes for the supervised classifier, duplicated and multiplicated clones are omitted in this table. The 41 genes are classified into two groups, “F > UF” and “F < UF,” when the expression in favorable samples is higher than that in unfavorable samples, and vice versa, respectively. In each group, genes are sorted by log rank p values. The log rank p value for each gene was calculated by comparing survival curves of two patient groups, in which the expression of the gene is higher and lower, respectively, than the median over the samples. A “q value” of a gene denotes the estimated false discovery rate among the genes whose p value is the same or smaller than that of the gene, and is a p-like value while incorporating multiplicity of the statistical test.
tained from 136 primary neuroblastomas. The highly reliable statistical analysis by using a neuroblastoma proper cDNA microarray harboring 5340 genes based on an electrically controlled ceramics-based ink-jet method led us to design a cDNA microarray system harboring 200 genes, which is applicable to short-term (2 year) and long-term (5 year) prognosis predictions for neuroblastoma.

Our study demonstrated that the supervised classifier produced by the 5340 genes system provided a high accuracy (88.5%) for the 5 year outcome prediction, with a good balance between sensitivity (88.6%) and specificity (89.4%). Although age at diagnosis, disease stage, MYCN amplification, and patients found by mass screening have been useful prognostic markers currently used at the bedside, most of them have either high sensitivity or high specificity (Table 1). The microarray analysis showed the best sensitivity-specificity balance among the prognostic factors for predicting the outcome of neuroblastoma. When the classifier is combined with the age at diagnosis, the disease stage (stage 1, 2, or 4s versus stage 3 or 4) and the MYCN amplification, accuracy, sensitivity, and specificity increased up to 95.8%, 93.3%, and 97.0%, respectively. Furthermore, the intermediate subset of neuroblastomas (type II), for which a long-term prognosis is usually difficult to make, was also categorized by microarray analysis into groups of patients with a favorable prognosis and those with an unfavorable prognosis. These successful results led us to produce a more practical tool at the bedside, the mini-chip system, whose accuracy, sensitivity, and specificity were 87.8%, 76.5%, and 93.8%, respectively, when the classifier constructed by the 5340 genes system was applied to 50 independent samples measured by the mini-chip system, and were 91.8%, 82.4% and 96.9%, respectively, when another classifier was constructed by applying the LTO procedure to the same data (Figure 4).

It is well recognized now that gene expression analyses for cancer prognosis prediction should pay close attention to the reproducibility of obtained results. A complete crossvalidation analysis without introducing any information leakage and an independent test using new samples are necessary. Although the determination of the appropriate number of genes used in supervised classifiers should be included in the validation procedure, it has often been ignored in most microarray studies. van 't Veer et al. (2002) applied the supervised classification to the breast cancer gene signature, which is predictive of a short interval to distant metastases in 78 patients who were initially devoid of local lymph node metastasis. Although their cross-validation analysis without the validation of the number of genes correctly predicted the actual outcome of disease for 63 of 78 patients (80.7%), the accuracy was worse when a complete validation was applied (73.1%). This difference suggests that even small information leakage may lead to overestimation of the accuracy. Beer et al. (2002) applied the supervised classification to the outcome prediction of lung adenocarcinoma. Their statistical analysis was complete without any information leakage. They did not report the prediction accuracy, but we estimated the accuracy to be about 70% from the data in their paper and found that the prediction by their supervised classifier was not very superior to that by existing prognosis markers. Iizuka et al. (2003) applied the supervised classification to the prediction of intrahepatic recurrence within 1 year after curative surgery for hepatocellular carcinoma patients. Although their predictor showed sufficiently high accuracy in an independent test with 27 samples, their crossvalidation procedure excluded the validation of the determination process of the number of optimum genes (steps 5 and 6 in their algorithm). The high crossvalidation accuracy of 100% may be an overestimation due to the information leakage.

According to the recent study that evaluated statistical methodologies used by microarray studies published between 1995 and April 2003, the three papers above were the only ones that reported both fairly sound crossvalidation analyses and independent tests (Ntzani and Ioannidis, 2003). Our LTO procedure includes the validation process of the number of genes used in the classifier and hence is a complete crossvalidation process. In addition, the obtained classifier was applied to the 50 independent samples that were measured by the reduced 200 genes system. This is a stronger test than usual independent tests but is important for the development of a practical system at the bedside. In addition, our LTO analysis achieved an almost unbiased estimation of the accuracy. Our crossvalidation analysis using the LTO procedure, the independent test of the classifier, and the validation of the procedure itself within a new experimental environment using the mini-chip system exhibited one of the most conservative and reliable statistical methodologies. In addition, our gene selection procedure according to the pairwise F score tries to extract correlation structures among genes, based on an idea similar to the exhaustive optimization method used in Iizuka et al. (2003), is beneficial in enhancing the applicability of the mini-chip system to various prediction problems, namely, short-term and long-term outcome predictions.

In addition to high accuracy, another advantage of our method is to provide a type of predictive information beyond the conventional binary prediction like favorable and unfavorable, which is ambiguous. The probabilistic output based on the hypothetical distribution obtained by the LTO analysis, the posterior probability, was found to show good accordance with actual survival rate (right bottom panel in Figure 2); this enables us to make a simple interpretation of the output: a patient with a posterior value of 0.8 has 80% chance for the 5 year survival, for example. Moreover, by calculating posterior probabilities for various future time points, a survival chance curve for each patient can be depicted (Figure 6). Although the follow-up period of patient “S057” is 2 years, and the patient is alive at this time, the individual survival chance curve says that his/her survival chance estimated from the gene expression pattern at diagnosis will get smaller than 50% at about 3 years after diagnosis. Such an individual survival chance curve can be used in choosing a suitable therapeutic protocol.

Another advantage of our method is that the probabilistic output is very stable in the presence of noise. Even when an artificial noise, whose variance is as large as the estimated noise variance of microarray, was added to expression profile data, prognosis prediction did not degrade very much (Figure S8). This robustness was confirmed when the noise variance went up to 1.0, which was sufficiently greater than the actual reproduction noise level of 0.4 (Figures S1A–S1C).
The high outcome predictability of our system is attributable to multiple reasons. The quality of tumor samples is high because (1) an appropriate system was established for our neuroblastoma tissue bank, and (2) handling of tumor tissues is rather uniform at each hospital, in which informed consent was obtained. An array, produced by a new apparatus equipped with a piezo microceramic pump, generates highly reproducible signals. The noncontact spotting method makes the spot shape almost a perfect circle. Consequently, the spot excels in signal uniformity. We did not conduct microdissection of the 136 tumor samples, because the stromal components of the tumor, e.g., Schwannian cells, are already known to be very important to characterize its biology (Ambros and Ambros, 1995; Ambros and Ambros, 2000). Therefore, a good combination or selection of these procedures may have provided high outcome predictability. In addition, the high predictability was reliably confirmed by the complete crossvalidation analysis and the independent test. The probabilistic output based on the LTO analysis can provide a new type of information that will improve the therapeutic decision at the bedside. In addition, the probabilistic output is highly robust against noises that may be involved in test samples (described above); this can be the major reason for the high prediction accuracy when the classifier constructed by the 5340 genes system was applied to the data taken by the mini-chip system.

The impact of the selected genes is strong. The genes with the highest score in F group genes (F > UF) were tubulin α members (TUBA3 and K-ALPHA-1, which corresponds to TUBA1), which have never been reported to be prognostic factors in neuroblastoma. Their prognostic significance has also been confirmed by RT-PCR in primary tumors (data not shown). The high expression of TUBA1 in neuronal cells is associated with axonal outgrowth during development as well as with axonal degeneration after axotomy in adult animals (Knoops and Octave, 1997). The expression of TUBA3 has been reported to be restricted to adherent, morphologically differentiated neuronal and glial cells (Hall and Cowan, 1985). We have also found that high expression of tubulin tyrosine ligase and enhanced tubulin tyrosination/detyrosination cycle are associated with neuronal differentiation in neuroblastomas with favorable prognosis (Kato et al., 2004). Thus, high mRNA expression of TUBA genes in favorable neuroblastoma may reflect differentiated status of tumors. ARHGEF7, Rho guanine nucleotide exchange factor 7, activates Rho proteins by exchanging bound GDP for GTP and can induce membrane ruffling. In our previous paper, we found that many family members of such G protein-related genes are highly expressed in favorable neuroblastomas compared to unfavorable ones (Ohira et al., 2003a). This may also imply a neuronal maturity nature of favorable tumors. Peripherin, a type III intermediate filament protein, was initially found as a cytoskeletal protein in the peripheral nervous system and in cultured cells of neuronal origin. This protein is known to be a marker of terminal neuronal differentiation; however, its functional role in neuroblastoma has been elusive. The previous evidence indicates that peripherin is transcriptionally upregulated by treatment with NGF, an important neurotrophin in neuroblastoma, and that the protein product is directly phosphorylated by NGF receptor, TrkA (Aletta et al., 1989). Thus, peripherin may play an important role as one of the signal transduction components involved in elaboration and maintenance of neuronal differentiation. In the UF gene group, many ribosomal protein-related genes are selected. GNB2L1, a receptor for activated C-kinase RACK1, is implicated in linking between PKC signaling and ribosome activation (Ceci et al., 2003). The DDX1 gene, which is frequently coamplified with the MYCN gene in advanced neuroblastomas (Godbout and Squire, 1993; Noguchi et al., 1996), is also a member of this group. Its protein product is a putative RNA helicase and is implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. DDX1 is ranked at a higher score than the MYCN gene, which is concordant with the previous reports describing that MYCN mRNA expression is a weaker prognostic marker than its genomic amplification (Slavc et al., 1990). Another important prognostic factor, TrkA, is not included in the top 70 genes but in the 90 (in the top 20 genes when the 5 year label was used) (data not shown), probably due to its relatively low levels of mRNA expression as compared with those of other genes. The prognosis-
The histological assessment of a surgically resected tumor specimen at preprocess for reliable prediction. We omitted the genes whose standard ranged between 3 and 241 months (median, 56 months; mean, 57.3 prediction, 126 samples whose 2 year prognosis is known were used. Se-tabolites at the age of 6 months, which has been performed nationwide in cessfully checked, were used to train a supervised classifier that predicts prognosis markers, were effectively separated into favorable known cDNAs that were thought to be neuroblastoma-related genes, we outcomes of patients belonging to the intermediate subset, of 200 cDNAs microarray on glass slides by the same procedure describedsisting of 41 stage 1 tumors, 22 stage 2 tumors, 33 stage 3 tumors, 28 stage 4 tumors, and 12 stage 4s tumors. Among the 136 fresh neuroblastomas, seventeen tumors were obtained at the delayed primary surgery after giving chemotherapy, but the other 119 tumors were resected by biopsy or surgery without giving any therapy. After surgery, patients were treated according to the previously described common protocols (Kaneko et al., 1998). Biological information on each tumor, including MYCN gene copy number, TrkA gene expression, and DNA ploidy, was analyzed in our laboratory, as described previously (Hishiki et al., 1998). All the tumors were classified ac-cording to the International Neuroblastoma Staging System (INSS) (Brodeur et al., 1993). The stage 4s neuroblastoma shows a special pattern of clinical behaviors, and the tumor itself, as well as its widespread metastases to the skin, liver, or bone marrow, usually regresses spontaneously. For a better understanding of statistical results, we introduced Brodeur’s classification of neuroblastoma subsets: type I (stages 1, 2, or 4s; a single copy of MYCN; blue marks in Figure 2), type II (stage 3 or 4; a single copy of MYCN; green marks in Figure 2), and type III (all stages; amplification of MYCN; red marks in Figure 2) (Brodeur and Nakagawara, 1992). Among 136 tumors that we analyzed, 66 were found by mass screening of urinary catecholamine me-tabolites at the age of 6 months, which has been performed nationwide in Japan from 1984 to 2004 (Sawada et al., 1984). The follow-up duration ranged between 3 and 241 months (median, 56 months; mean, 57.3 months) after diagnosis. All diagnoses of neuroblastoma were confirmed by the histological assessment of a surgically resected tumor specimen at each hospital. Shimada’s classification (Shimada et al., 1984) was per-formed in 62 out of 136 cases. The macroscopic necroses in the tumor were excluded from the tissue sampling for molecular analysis. We used for the microarray analysis only the tumor samples whose adjacent tissues contained more than 70% tumor cells in the thin sections stained with he-matoxylin–eosin. For independent test, 50 (19 were found by mass screen-ing and 31 were clinically found) tumors (15 of stage 1, 6 of stage 2, 9 of stage 3, 14 of stage 4, and 6 of stage 4s) were used. Total RNA was extracted from each frozen tissue according to the AGPC method (Chomczynski and Sacchi, 1987). RNA integrity, quality, and quan-ity were then assessed by electrophoresis on the Agilent RNA 6000 na-nochip using Agilent 2100 BioAnalyzer (Agilent Technologies, Inc.).

cDNA microarray experiments
We previously obtained approximately 5,000 genes after selecting from 10,000 clones randomly picked up from the mixture of oligo-capping cDNA libraries, which were generated from three primary neuroblastomas with a favorable outcome (stage 1; high TrkA expression and a single copy of MYCN), three tumors with a poor prognosis (stage 3 or 4; low expression of TrkA and amplification of MYCN), and a stage 4s tumor (Ohira et al., 2003a; Ohira et al., 2003b). Using these isolated genes together with 80 known cDNAs that were thought to be neuroblastoma-related genes, we first constructed a neuroblastoma proper cDNA microarray (named CCG-NB5000-Chip) carrying 5340 cDNA spots (the 5340 genes system). Insert DNAs (average size, approximately 2.5kb) were amplified by polymerase chain reaction (PCR) from these cDNA clones, purified by ethanol precipita-tion, and spotted onto a glass slide at a high density with an ink-jet printing tool (NGK Insulators, Ltd.). Ten micrograms each of total RNA were labeled with the CyScribe RNA labeling kit in accordance with the manufacturer’s manual (Amersham Pharmacia Biotech), followed by probe purification with the Qiagen MinElute PCR purification kit (Qiagen). We used a mixture of equal amounts of RNA from each of four neuroblastoma cell lines (NB69, NBL-S, SK-N-AS, and SH-SY5Y) as a reference. RNAs extracted from primary neuroblastoma tis-sues and RNAs of the reference mixture were labeled with Cy3 and Cy5 dye, respectively, and were used as probes together with yeast tRNA and polyA for suppression. Subsequent hybridization and washing were con-ducted as described previously (Takahashi et al., 2002; Yoshikawa et al., 2000). Hybridized microarrays were scanned using the Agilent G2505A con-focal laser scanner (Agilent Technologies, Inc.), and fluorescent intensities were quantified using the GenePix Pro microarray analysis software (Axon Instruments, Inc.). The procedure of this study was approved by the Institu-tional Review Board of the Chiba Cancer Center. For independent test, 50 samples, tumor RNA preparation, probe labeling, and hybridization were conducted in a completely different laboratory from the original 136 hybridization. In this independent test, 5 μg each of total RNA were used for labeling.

Data preprocessing
To remove chip-wise biases of a microarray system, we used the LOWESS normalization (Cleveland, 1979). When the Cy3 or Cy5 strength for a clone was smaller than 3, strength was regarded as abnormally small, and the log expression ratio of the corresponding clone was treated as a missing value. The rate of such missing entries was less than 1%. After normalizing the 5340 (genes) by 136 (samples) log expression matrix and removing missing values, each missing entry was imputed to an estimated value by Bayesian principal component analysis, which was developed previously (Oba et al., 2003).

Supervised machine learning and LTO crossvalidation
The 96 samples, whose prognosis at 5 years after diagnosis had been suc cessfully checked, were used to train a supervised classifier that predicts the 5 year prognosis of a new patient. When we considered the short-term prediction, 126 samples whose 2 year prognosis is known were used. Se-lection of the genes that are related to the classification is an important preprocess for reliable prediction. We omitted the genes whose standard
deviation of the log ratios for the genes obtained over 136 experiments was smaller than 0.36, so that 1000 genes remained, because the background noise level was about 0.2–0.3. After the gene screening, the genes were scored by the pairwise F score, which is a modification of a pairwise correlation method (Bo and Jonassen, 2002), to conduct gene ranking in an attempt not only to obtain higher discrimination accuracy by using a smaller number of genes but also to reserve the applicability to various outcome prediction by the set of selected genes (see the Supplemental Data).

We used a well-established technique in the supervised classification (prognosis prediction), that is, weighted voting with linear discriminators, where each weight value was calculated as the signal-to-noise ratio (Golub et al., 1999). In the weighted voting, only n genes with the largest pairwise F score were used. The number of top genes, n, strongly affects the prediction accuracy (Figure S3) as found in various microarray studies and hence should be determined such to maximize the leave one out (LOO) crossvalidation accuracy. However, a naive determination process of n may introduce information leakage, and the accuracy optimized by the LOO cross-validation involves overestimation. To avoid such an overestimation, we consulted a LTO analysis. The LTO analysis was constituted of inner and outer loops of LOO (Figure S2A); the gene number n was optimized by the LOO crossvalidation repeating the inner loops, and the optimized classifier was evaluated by an independent test for a single sample left out at a single step in the outer loop. During repetition of such steps, the test results of the outer loop were never fed back to the classifier’s optimization process in the inner loops, and hence the tests in the outer loop did not include any overestimation, and the estimated accuracy involved the smallest bias as possible.

The posterior value for a single sample was calculated based on the distribution of the weighted vote (decision by majority by the genes that join the vote) f within the LTO analysis. We regard a real-valued weighted vote as carrying two kinds of information: its sign predicts the label (favorable or unfavorable) of the corresponding sample, and its absolute value shows the prediction strength. The posterior probability p for this sample being favorable (alive at 5 years) was evaluated as the logit transformation \( p = \exp(\beta_0 + \beta_1 f/1 + \exp(\beta_0 + \beta_1 f)) \), where parameters \( \beta_0 \) and \( \beta_1 \) were estimated by the maximum likelihood method, in each step in the outer loop of LTO using the remaining 95 samples and the corresponding labels (5 year prognosis).

Then, the posterior probability of the sample left out in the outer loop was predicted by the weighted vote f by the classifier constructed in the inner LOO loops and the parameters \( \beta_0 \) and \( \beta_1 \) obtained above. There is therefore no information leakage in this calculation process of the posterior of the sample left out.

Independent test
Using the 50 independent samples, we performed two kinds of tests. The first one is an independent test to validate the classifier obtained by our method and the applicability of our classifier to the mini-chip system, which has been developed as a clinical tool at the bedside (Figure S2B). According to the LTO analysis, the supervised classifier was finally constructed by using all of the 96 training samples measured by the 5340 genes system. This classifier was evaluated by being directly applied to the 50 samples measured by the mini-chip system without any information from measurements by the mini-chip system and the 50 test samples. In this test, tumor RNA preparation, probe labeling, and hybridization were conducted in a completely different laboratory from that for the 5340 genes system. The second one is to validate the LTO analysis to construct a supervised classifier by applying the procedure to the data taken by the mini-chip system.

Survival analysis
The Kaplan–Meier survival analysis was also programmed and used to compare patient survival. To assess the association of selected gene expression with patient clinical outcome, the statistical p and q values were calculated based on the log rank test.

Immunohistochemistry
Immunostaining with the antibody against peripherin protein (Santa Cruz Biotechnology; 1:400) was performed on six human neuroblastoma tumors selected from the surgical pathology file at the Department of Pathology, Aichi Medical University. They were all neuroblastoma (Schwannian stroma—poor) and included three favorable histology tumors (poorly differentiated subtype without MYCN amplification [one case]; differentiated subtype without MYCN amplification [two cases]) and three unfavorable histology tumors (undifferentiated subtype without MYCN amplification [one case]; poorly differentiated subtype with MYCN amplification [one case]; poorly differentiated subtype without MYCN amplification). All tumor tissues were obtained prior to chemotherapy and irradiation therapy. Four micron thick sections from the formalin-fixed, paraffin-embedded samples of these tumors were treated according to the protocol described previously (Kato et al., 2004). As for the negative controls, normal goat immunoglobulins (1:500 dilution; Vector Laboratories) were applied as the primary antibody.

Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and ten supplemental figures and can be found with this article online at http://www.cancerres.org/cgi/content/full/65/7/3370/DC1/.

Acknowledgments
We are grateful to the hospitals and institutions that provided us with surgical specimens (see the Supplemental Data). We also thank Shigeru Sakiyama and John K. Cowell for reading the manuscript; Naohiko Seki, Tsumoru Yoshikawa, and Masaki Kato for their valuable suggestions; and Natsuki Kitabayashi, Tomonori Saito, Naoko Sugimtusu, Yuki Nakamura, Naoko Shibano, Emiko Kojima, Hisae Murakami, and Kazumi Yagyu for their technical support. This work was supported in part by a fund from Hisamitsu Pharmaceutical Co., Inc.; by Grants-in-Aid for Scientific Research on Priority Areas (C) “Medical Genome Science” and “Genome Information Science” and for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and by Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan.

Received: November 17, 2003
Revised: January 8, 2005
Accepted: March 11, 2005
Published: April 18, 2005

References
Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E., and Bishop, J.M.
(1984). Amplification of N-myc in untreated human neuroblastomas corre-
lates with advanced disease stage. Science 224, 1121–1124.


Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L., Castel, V., Castel-


Hall, J.L., and Cowan, N.J. (1985). Structural features and restricted expres-

derived neurotrophic factor/neurturin-induced differentiation and its en-
hancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR-derived neurotrophic factor/neurturin-induced differentiation and its en-
hancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR.

Knoops, B., and Octave, J.N. (1997). Structural features and restricted expres-
sion of a human α-tubulin gene in neuroblastoma as a result of cosegregation of sequences flanking the p33(ING1)-regulated genes that include cyclin B1 and proto-oncogene in retinoblastoma cell lines expressing c-Ret, GFR-α1, and GFR-α2. Cancer Res. 58, 2158–2165.

484–491. The high level of c-myc gene amplification and expression in primary neuroblastomas: identification of 305 genes differentially ex-
pressed between favorable and unfavorable subsets. Oncogene 22, 5525–
5536.


Ohira, M., Morohashi, A., Inuzuka, H., Shishikura, T., Kawamoto, T., Kage-
pressed between favorable and unfavorable subsets. Oncogene 22, 5525–
5536.


Schwab, M., Alitalo, K., Klemmepner, K.H., Varmus, H.E., Bishop, J.M., Gil-
be, F., Brodeur, G., Goldstein, M., and Trent, J. (1983). Amplified DNA with limited homology to myc cellular oncogene is shared by human neuro-


Storey, J.D., and Tibshirani, R. (2003). Statistical significance for genome-

Takahashi, M., Seki, N., Ozaki, T., Kato, M., Kuno, T., Nakagawa, T., Wata-

164.

CANCER CELL : APRIL 2005 349


Accession numbers
Microarray data are available at NCBI Gene Expression Omnibus (accession number GSE2283).